Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes

NCT: NCT07087353 · RECRUITING

NCT IDNCT07087353
StatusRECRUITING
Start Date2025-10-31
Completion2027-12-01

Brief Summary

Mood disorders like depression and bipolar disorder are widespread and cause serious psychological, cognitive, and social impairments, with a high burden on healthcare systems. Edra PRO is a digital medical device developed to support clinical decision-making and remotely monitor symptoms in psychiatric patients. The EC-102 randomized controlled trial will evaluate its impact compared to usual care on symptoms, quality of life, healthcare costs, comorbidities, and user adherence and satisfaction.

Frequently Asked Questions

What is Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes?

Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes is a clinical trial registered under NCT07087353. Current status: RECRUITING.

What is the status of NCT07087353?

The current status of NCT07087353 (Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes) is: RECRUITING.

When did Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes start?

Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes started on 2025-10-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑